Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
1.1
-8x
Never
—
-19.71%
40%
—
5 Years
Score1.1
Net Growth-8x
Net TrendNever
Net Income Consistency—
Rev Growth-19.71%
Rev Trend40%
Revenue Consistency—
Vanda Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 248M to $ 216M and net income went from $ 23M to -$ 220M. Revenue increased in 2 of those 5 years; net income in 0.
Between 2015 and 2025, revenue grew from $ 109M to $ 216M and net income went from -$ 39M to -$ 220M. Revenue increased in 7 of those 10 years; net income in 4.
Vanda Pharmaceuticals Inc currently holds a 5-year HDB Score of 1.1 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 5.19 | — |
1 Year2025-08-12 | $ 4.31 | 20.42% |
5 Years2021-08-12 | $ 16.20 | -67.96% |
10 Years2016-08-12 | $ 12.80 | -59.45% |
20 Years2006-08-11 | $ 9.94 | -47.79% |
All Time2006-04-12 | $ 9.68 | -46.38% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | All Time2006-04-12 |
|---|---|---|---|---|---|---|
| Price | $ 5.19 | $ 4.31 | $ 16.20 | $ 12.80 | $ 9.94 | $ 9.68 |
| Return | — | 20.42% | -67.96% | -59.45% | -47.79% | -46.38% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 215M | -$ 274M | $ 170M |
| 2025 | $ 216M | -$ 220M | $ 263M |
| 2024 | $ 198M | -$ 18M | $ 374M |
| 2023 | $ 192M | $ 2M | $ 388M |
| 2022 | $ 254M | $ 6M | $ 466M |
| 2021 | $ 268M | $ 33M | $ 432M |
| 2020 | $ 248M | $ 23M | $ 367M |
| 2019 | $ 227M | $ 115M | $ 312M |
| 2018 | $ 193M | $ 25M | $ 257M |
| 2017 | $ 165M | -$ 15M | $ 143M |
| 2016 | $ 146M | -$ 18M | $ 141M |
| 2015 | $ 109M | -$ 39M | $ 143M |
| 2014 | $ 50M | $ 20M | $ 129M |
| 2013 | $ 33M | -$ 20M | $ 130M |
| 2012 | $ 32M | -$ 27M | $ 120M |
| 2011 | $ 31M | -$ 9M | $ 148M |
| 2010 | $ 35M | $ 7M | $ 198M |
| 2009 | $ 4M | -$ 35M | $ 205M |
| 2008 | -$ 51M | $ 46M | |
| 2007 | -$ 74M | $ 85M | |
| IPO2006 | -$ 63M | $ 31M |
Explore beyond VNDA
You're looking at Vanda Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
